Navigation Links
Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis

at the company’s upcoming R&D day on June 20, 2007 at 2 pm (CET) and provide then further details about preclinical and clinical results.


About the combined phase I/IIa study

The multi-centre, randomized, placebo-controlled and double-blind study included 48 male and female patients suffering from moderate to severe plaque psoriasis. An initial part of the study with a total of 24 participants evaluated the safety and tolerability of ascending doses of the vaccine (100 ?g, 300 ?g). It was followed by a second study part with a total of 24 participants that was designed to evaluate exploratory efficacy of the highest previously tested vaccine dose (i.e. 300 ?g) compared to placebo. Patients of this latter group were randomized 1:1 into the vaccine-treated and the placebo group and either received 5 subcutaneous injections of 300 ?g CYT007-TNFQb or placebo at weeks 0, 2, 4, 8 and 12. Upon entry into the study and then every two weeks up to week 16, the patients’ disease severity was determined by the Psoriasis Area and Severity Index (PASI).

About psoriasis and CYT007-TNFQb

Psoriasis is a common chronic skin disorder that affects 1-3% of the world’s population (National Psoriasis Foundation, USA). Plaque psoriasis is the most common form of the disease (>80% of cases) and it is characterized by inflamed red patches of skin topped with silvery white scales. While there are a number of medications that may help to control the symptoms of psoriasis, there is as yet no cure. Psoriasis is considered to be linked to an overactive immune system where inflammatory cytokines play an essential role. The inflammatory cytokine tumor necrosis factor alpha (TNF-?) has been described as a key molecule in the pathogenesis of psoriasis. Consequently, recently approved anti-TNF-? biologics have proven effective; however, they have to be administered frequently and at high doses and are therefore associated
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
(Date:7/1/2015)... The Haselmeier Group has decided to reinforce ... has been nominated by the Board of Directors ... (CEO) of the Haselmeier Group. This nomination is ... brings more than 20 years of experience in the ... management positions, the last being Managing Director and Vice ...
(Date:6/30/2015)... -- Inventor of ProTide technology ...   NuCana, a clinical stage biopharmaceutical company ... portfolio of novel anti-cancer medicines, today announced the appointment ... Officer. Professor McGuigan was the original inventor ... Medicinal Chemistry at the Cardiff School of Pharmacy and ...
(Date:6/30/2015)... Ansell, a global leader in protection solutions, ... Ansell Cares ® H.E.R.O. Service Award ... organised in partnership with the European Operating Room Nurses ... and quality in patient care, and present an in-depth ... taking place today in the winners, respective hospitals in ...
Breaking Medicine Technology:Haselmeier Group Announces the Extension and Reorganization of its Executive Board 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 2Internationally Renowned Medicinal Chemist Professor Chris McGuigan Appointed as NuCana's Chief Scientific Officer 3Ansell Announces European O.R. Nurse Hero Award Winners 2Ansell Announces European O.R. Nurse Hero Award Winners 3
... SAN DIEGO, May 5, 2011 /PRNewswire/ -- Halozyme ... developing and commercializing products targeting the extracellular matrix , ... of America Merrill Lynch Health Care Conference in Las Vegas. ... PDT (2:10 p.m. EDT). To listen to the live webcast ...
... 2011 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... 31, 2011.  Savient ended the quarter with $268.0 million in ... December 31, 2010, primarily due to the issuance and sale ... the first quarter of 2011, the Company had a net ...
Cached Medicine Technology:Halozyme Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference on May 12 2Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports First Quarter 2011 Financial Results 7
(Date:7/1/2015)... ... July 01, 2015 , ... Northbound Treatment Services announced today ... Relations. , Emily originally entered the behavioral healthcare industry as an academic ... academic curriculum for clients to engage in their educational journey while in treatment. ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... dedicated to the global distribution and marketing of a number of nutritional and ... when it attended the 2015 ECRM Diet, Vitamin & Sports Nutrition conference in ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... different philosophies and approaches to case management, placement, sober companionship and delivery to ... and approaches to working with and transporting clients with anxiety, ADHD, autism spectrum ...
(Date:7/1/2015)... ... ... The Thule Atmos X4 offers protection with minimal bulk. At the Thule ... rigorous standards. Due to its Bi-ComponentArmor and ShockStop corners, it passed Thule’s 2 meter ... , The Thule Atmos X4 has also been designed with function in mind. ...
(Date:7/1/2015)... (PRWEB) , ... July 01, ... ... in the communities of southeast Alabama, southwest Georgia and the Florida Panhandle, ... TelmedIQ as its primary secure text messaging and clinical communications workflow solution ...
Breaking Medicine News(10 mins):Health News:Northbound Treatment Services Welcomes Emily Orrick as Director of Referral Relations 2Health News:NPI Executives Report Great Success at ECRM Conference 2Health News:All Kinds of Therapy – Announces New Partnership Feature, Therapeutic Experts 2Health News:Southeast Alabama Community Health System Chooses TelmedIQ to Meet Secure Text Messaging Challenges for Healthcare 2
... 3 Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) today ... will provide a corporate,overview at the upcoming Collins Stewart ... July 8, 2008 in New York, NY., Interested ... visiting,the Sunesis website at http://ir.sunesis.com . A replay ...
... Rigel Pharmaceuticals,Inc. (Nasdaq: RIGL ) today announced that ... will present a company overview,at the Fourth Annual Collins ... a.m. EDT at The Mandarin Oriental Hotel in New ... or the subsequent archived recording,log on to http://www.rigel.com ...
... 2 The Michigan Attorney General announced,on July 2 ... Shield of,Michigan challenging a capital transaction between BCBSM and ... position that BCBSM is not,authorized by Public Act 350 ... Accident Fund obtained prior regulatory approval for the,transaction. BCBSM ...
... has spread to distant sites has a poor prognosis, but ... slow disease progression in some patients, a research team led ... Cancer Center reports in the July 3rd edition of ... drug, motesanib diphosphate, is a VEGF inhibitor, a biologic agent ...
... 2 A Miami resident was,sentenced to 130 months ... the,Medicare program, Acting Assistant Attorney General Matthew Friedrich of,the ... the Southern,District of Florida announced today., Gustavo Smith, ... for,the Southern District of Florida by Judge Marcia G. ...
... Hanger Orthopedic,Group, Inc. (NYSE: HGR ) ... Services revised its outlook for Hanger Orthopedic Group, ... corporate credit,rating at "B." "The outlook revision reflects ... improved financial risk profile," said,Standard & Poor,s credit ...
Cached Medicine News:Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 2Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 3Health News:Blood vessel inhibitor shows promise against metastatic thyroid cancer 4Health News:Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud 2Health News:Owner of Medical Equipment Company Sentenced to 130 Months in Prison for Health Care Fraud 3Health News:Hanger Orthopedic Group, Inc. Receives Positive Outlook from Standard & Poor's Rating Services 2
Designed to be removed from under surgical gown without compromising sterile fields. Two straps criss-cross in the back and attach with velcro in the front....
Wolfs unique apron and vest set distributes weight evenly between shoulders and hips. The vest comes with an attached Thyroid collar...
... Full frontal protection, our conventional ... shoulders by sturdy 2 webbed ... quick-acting snap hook fasteners. The ... custom fit the apron. Our ...
... Aprons are the result of a technologically ... x-ray aprons. Constructed with a wear resistant, ... the Lead Free aprons exhibit the same ... Each apron weighs approximately 50% less than ...
Medicine Products: